Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Financial Performance and Industry Comparison

Core Insights - Alnylam Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for genetically defined diseases, positioning itself competitively against peers like BioMarin, Ionis, Sarepta, and Agios [1] Financial Performance - Alnylam's Return on Invested Capital (ROIC) is 13.74%, while its Weighted Average Cost of Capital (WACC) is 5.66%, resulting in a ROIC to WACC ratio of 2.43, indicating efficient capital use [2][6] - In comparison, BioMarin has a ROIC of 5.64% and a WACC of 4.73%, yielding a ROIC to WACC ratio of 1.19, which is lower than Alnylam's [3] - Ionis and Sarepta exhibit negative ROIC to WACC ratios of -2.37 and -5.41, respectively, indicating insufficient returns to cover their cost of capital [4] - Agios also shows a negative ROIC to WACC ratio of -4.93, further highlighting Alnylam's strong performance in the industry [5][6]